Učitavanje...
Laquinimod in the treatment of multiple sclerosis: a review of the data so far
Laquinimod (ABR-215062) is a new orally available carboxamide derivative, which is currently developed for relapsing remitting (RR) and chronic progressive (CP) forms of multiple sclerosis (MS; RRMS or CPMS) as well as neurodegenerative diseases. Its mechanism of action may comprise immunomodulatory...
Spremljeno u:
| Izdano u: | Drug Des Devel Ther |
|---|---|
| Glavni autori: | , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
Dove Medical Press
2016
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4798201/ https://ncbi.nlm.nih.gov/pubmed/27042003 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S55308 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|